Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery.

Mazer CD, Whitlock RP, Fergusson DA, Hall J, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Médicis É, McGuinness S, Royse A, Carrier FM, Young PJ, Villar JC, Grocott HP, Seeberger MD, Fremes S, Lellouche F, Syed S, Byrne K, Bagshaw SM, Hwang NC, Mehta C, Painter TW, Royse C, Verma S, Hare GMT, Cohen A, Thorpe KE, Jüni P, Shehata N; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.

N Engl J Med. 2017 Nov 30;377(22):2133-2144. doi: 10.1056/NEJMoa1711818. Epub 2017 Nov 12.

PMID:
29130845
2.

Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery.

Swaminathan M, Stafford-Smith M, Chertow GM, Warnock DG, Paragamian V, Brenner RM, Lellouche F, Fox-Robichaud A, Atta MG, Melby S, Mehta RL, Wald R, Verma S, Mazer CD; ACT-AKI investigators.

J Am Soc Nephrol. 2017 Oct 16. pii: ASN.2016101150. doi: 10.1681/ASN.2016101150. [Epub ahead of print]

PMID:
29038286
3.

Glutamine and antioxidants in the critically ill patient: a post hoc analysis of a large-scale randomized trial.

Heyland DK, Elke G, Cook D, Berger MM, Wischmeyer PE, Albert M, Muscedere J, Jones G, Day AG; Canadian Critical Care Trials Group.

JPEN J Parenter Enteral Nutr. 2015 May;39(4):401-9. doi: 10.1177/0148607114529994. Epub 2014 May 5.

PMID:
24803474
4.

Liver transplantation in the critically ill: a multicenter Canadian retrospective cohort study.

Karvellas CJ, Lescot T, Goldberg P, Sharpe MD, Ronco JJ, Renner EL, Vahidy H, Poonja Z, Chaudhury P, Kneteman NM, Selzner M, Cook EF, Bagshaw SM; Canadian Liver Failure Study Group.

Crit Care. 2013 Feb 9;17(1):R28. doi: 10.1186/cc12508.

5.

High-frequency oscillation in early acute respiratory distress syndrome.

Ferguson ND, Cook DJ, Guyatt GH, Mehta S, Hand L, Austin P, Zhou Q, Matte A, Walter SD, Lamontagne F, Granton JT, Arabi YM, Arroliga AC, Stewart TE, Slutsky AS, Meade MO; OSCILLATE Trial Investigators; Canadian Critical Care Trials Group.

N Engl J Med. 2013 Feb 28;368(9):795-805. doi: 10.1056/NEJMoa1215554. Epub 2013 Jan 22.

6.

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators.

Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5.

PMID:
21975206
7.

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.

Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A; Investigators of the 16-year Long-Term Follow-Up Study.

J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):907-12. doi: 10.1136/jnnp.2009.204123. Epub 2010 Jun 19.

PMID:
20562430
8.

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A; Investigators of the 16-Year Long-Term Follow-Up Study.

Neurology. 2010 Jun 8;74(23):1877-85. doi: 10.1212/WNL.0b013e3181e240d0.

PMID:
20530324

Supplemental Content

Loading ...
Support Center